Company news

Protara Therapeutics, Inc. news in 2026

Protara Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

October 15, 2026

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 11, 2026

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

May 15, 2026

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

May 13, 2026

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

April 27, 2026

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

March 9, 2026

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

February 22, 2026

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

January 22, 2026

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

January 12, 2026

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support

January 7, 2026

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

January 5, 2026

Calls in 2026

Decks in 2026